CompanySPRCNasdaqTel Aviv, L3

SciSparc Ltd.

SciSparc develops cannabinoid pharmaceuticals through clinical-stage subsidiary NeuroThera.

SEC EDGAR ClinicalTrials.gov amazon.com

6-KSep 30Latest SEC filing

Sep 24Latest story

September 2026

SciSparc's NeuroThera expands US patent filings on psychedelic-PEA combinations with Clearmind

Sep 24PartnershipSciSparc Ltd.

August 2026

SciSparc subsidiary NeuroThera advances MDMA-PEA patent with Clearmind for PTSD

Aug 24PartnershipSciSparc Ltd.

SciSparc subsidiary NeuroThera raises C$5.4 million in private placement financing

Aug 18FinancingSciSparc Ltd.

SciSparc's NeuroThera launches Tourette syndrome trial site at Yale

Aug 5Clinical readoutSciSparc Ltd.

July 2026

SciSparc's NeuroThera opens German Phase IIb site for Tourette drug SCI-110

Jul 15Clinical readoutSciSparc Ltd.